'Big'-insulin-like growth factor-II signaling is an autocrine survival pathway in gastrointestinal stromal tumors

American Journal of Pathology

Volumn 181, Issue 1, 2012, Pages 303-312

  Rikhof, Bart ^a   Van Der Graaf, Winette T A ^b   Suurmeijer, Albert J H ^a   Van Doorn, Jaap ^c   Meersma, Gert Jan ^a   Groenen, Patricia J T A ^b   Schuuring, Ed M D ^a   Meijer, Coby ^a   De Jong, Steven ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; INSULIN RECEPTOR; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; SOMATOMEDIN B; SOMATOMEDIN C RECEPTOR;

ARTICLE; AUTOCRINE EFFECT; CANCER SURVIVAL; CYTOTOXICITY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MUTANT; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AUTOCRINE COMMUNICATION; CELL DEATH; CELL SURVIVAL; DOWN-REGULATION; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INSULIN-LIKE GROWTH FACTOR II; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PIPERAZINES; PROTEIN PRECURSORS; PYRIMIDINES; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 84862639664     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2012.03.028     Document Type: Article

References (41)

1. Corless CL, Fletcher JA, Heinrich MC: Biology of gastrointestinal stromal tumors. J Clin Oncol 2004, 22:3813-3825
2. Gastrointestinal Stromal Tumor Meta-analysis Group: Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010, 28:1247-1253
3. Toretsky JA, Helman LJ: Involvement of IGF-II in human cancer. J Endocrinol 1996, 149:367-372
4. De Groot JW, Rikhof B, Van Doorn J, Bilo HJ, Alleman MA, Honkoop AH, Van der Graaf WT: Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases. Endocr Relat Cancer 2007, 14:979-993
5. Rikhof B, De Jong S, Suurmeijer AJ, Meijer C, Van der Graaf WT: The insulin-like growth factor system and sarcomas. J Pathol 2009, 217:469-482
6. Rikhof B, Van Doorn J, Suurmeijer AJ, Rautenberg MW, Groenen PJ, Verdijk MA, Jager PL, De Jong S, Gietema JA, Van der Graaf WT: Insulin-like growth factors and insulin-like growth factor-binding proteins in relation to disease status and incidence of hypoglycaemia in patients with a gastrointestinal stromal tumour. Ann Oncol 2009, 20:1582-1588
7. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA, Demetri GD: STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001, 20:5054-5058
8. Bauer S, Yu LK, Demetri GD, Fletcher JA: Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 2006, 66:9153-9161
9. Van der Deen M, De Vries EG, Visserman H, Zandbergen W, Postma DS, Timens W, Timmer-Bosscha H: Cigarette smoke extract affects functional activity of MRP1 in bronchial epithelial cells. J Biochem Mol Toxicol 2007, 21:243-251
10. De Groot DJ, Timmer T, Spierings DC, Le TK, De Jong S, De Vries EG: Indomethacin-induced activation of the death receptor-mediated apoptosis pathway circumvents acquired doxorubicin resistance in SCLC cells. Br J Cancer 2005, 92:1459-1466
11. Van Doorn J, Hoogerbrugge CM, Koster JG, Bloemen RJ, Hoekman K, Mudde AH, Van Buul-Offers SC: Antibodies directed against the E region of pro-insulin-like growth factor-II used to evaluate non-islet cell tumor-induced hypoglycemia. Clin Chem 2002, 48:1739-1750
12. Saperstein R, Vicario PP, Strout HV, Brady E, Slater EE, Greenlee WJ, Ondeyka DL, Patchett AA, Hangauer DG: Design of a selective insulin receptor tyrosine kinase inhibitor and its effect on glucose uptake and metabolism in intact cells. Biochemistry 1989, 28:5694-5701
13. Rikhof B, Van der Graaf WT, Meijer C, Le PT, Meersma GJ, De Jong S, Fletcher JA, Suurmeijer AJ: Abundant Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for MegaFasL. Br J Cancer 2008, 99:1600-1606
14. Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corless CL, Debiec-Rychter M, DeMatteo RP, Ettinger DS, Fisher GA, Fletcher CD, Gronchi A, Hohenberger P, Hughes M, Joensuu H, Judson I, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PW, Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, Von Mehren M, Wayne JD, Zalcberg J, NCCN Task Force: NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST) - update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007, 5 Suppl 2:S1-S29
15. Van Doorn J, Gilhuis HJ, Koster JG, Wesseling P, Reddingius RE, Gresnigt MG, Bloemen RJ, Van Muijen GN, Van Buul-Offers SC: Differential patterns of insulin-like growth factor-I and -II mRNA expression in medulloblastoma. Neuropathol Appl Neurobiol 2004, 30:503-512
16. Han VK, Bassett N, Walton J, Challis JR: The expression of insulin-like growth factor (IGF) and IGF-binding protein (IGFBP) genes in the human placenta and membranes: evidence for IGF-IGFBP interactions at the feto-maternal interface. J Clin Endocrinol Metab 1996, 81:2680-2693
17. El-Badry OM, Minniti C, Kohn EC, Houghton PJ, Daughaday WH, Helman LJ: Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ 1990, 1:325-331
18. Duguay SJ, Jin Y, Stein J, Duguay AN, Gardner P, Steiner DF: Post-translational processing of the insulin-like growth factor-2 precursor. Analysis of O-glycosylation and endoproteolysis. J Biol Chem 1998, 273:18443-18451
19. Diaz LE, Chuan YC, Lewitt M, Fernandez-Perez L, Carrasco-Rodriguez S, Sanchez-Gomez M, Flores-Morales A: IGF-II regulates metastatic properties of choriocarcinoma cells through the activation of the insulin receptor. Mol Hum Reprod 2007, 13:567-576
20. Rose PP, Carroll JM, Carroll PA, DeFilippis VR, Lagunoff M, Moses AV, Roberts CT, Früh K: The insulin receptor is essential for virus-induced tumorigenesis of Kaposi's sarcoma. Oncogene 2007, 26:1995-2005
21. Duensing A, Medeiros F, McConarty B, Joseph NE, Panigrahy D, Singer S, Fletcher CD, Demetri GD, Fletcher JA: Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 2004, 23:3999-4006
22. Zhu MJ, Ou WB, Fletcher CD, Cohen PS, Demetri GD, Fletcher JA: KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance. Oncogene 2007, 26:6386-6395
23. ElmLinger MW, Rauschnabel U, Koscielniak E, Weber K, Ranke MB: Secretion of noncomplexed 'Big' (10-18 kD) forms of insulin-like growth factor-II by 12 soft tissue sarcoma cell lines. Horm Res 1999, 52:178-185
24. Sun Y, Gao D, Liu Y, Huang J, Lessnick S, Tanaka S: IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1. Oncogene 2006, 25:1042-1052
25. Avnet S, Sciacca L, Salerno M, Gancitano G, Cassarino MF, Longhi A, Zakikhani M, Carboni JM, Gottardis M, Giunti A, Pollak M, Vigneri R, Baldini N: Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res 2009, 69:2443-2452
26. Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, Testa JR, Eisenberg B, Von Mehren M, Godwin AK: Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci USA 2008, 105:8387-8392
27. Agaram NP, Laquaglia MP, Ustun B, Guo T, Wong GC, Socci ND, Maki RG, DeMatteo RP, Besmer P, Antonescu CR: Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res 2008, 14:3204-3215
28. Janeway KA, Zhu MJ, Barretina J, Perez-Atayde A, Demetri GD, Fletcher JA: Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification. Int J Cancer 2010, 127:2718-2722
29. Pantaleo MA, Astolfi A, Di Battista M, Heinrich MC, Paterini P, Scotlandi K, Santini D, Catena F, Manara MC, Nannini M, Maleddu A, Saponara M, Lolli C, Formica S, Biasco G: Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target. Int J Cancer 2009, 125:2991-2994
30. Braconi C, Bracci R, Bearzi I, Bianchi F, Sabato S, Mandolesi A, Belvederesi L, Cascinu S, Valeri N, Cellerino R: Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Ann Oncol 2008, 19:1293-1298
31. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A, Vigneri R: Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 1999, 19:3278-3288
32. Bauer S, Duensing A, Demetri GD, Fletcher JA: KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: pI3-kinase/AKT is a crucial survival pathway. Oncogene 2007, 26:7560-7568
33. Rossi F, Ehlers I, Agosti V, Socci ND, Viale A, Sommer G, Yozgat Y, Manova K, Antonescu CR, Besmer P: Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci USA 2006, 103:12843-12848
34. Ou WB, Zhu MJ, Demetri GD, Fletcher CD, Fletcher JA: Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors. Oncogene 2008, 27:5624-5634
35. Steigen SE, Schaeffer DF, West RB, Nielsen TO: Expression of insulin-like growth factor 2 in mesenchymal neoplasms. Mod Pathol 2009, 22:914-921
36. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC: KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002, 160:1567-1572
37. Kawanowa K, Sakuma Y, Sakurai S, Hishima T, Iwasaki Y, Saito K, Hosoya Y, Nakajima T, Funata N: High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol 2006, 37:1527-1535
38. Agaimy A, Wunsch PH, Hofstaedter F, Blaszyk H, Rümmele P, Gaumann A, Dietmaier W, Hartmann A: Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 2007, 31:113-120
39. Hartog H, Wesseling J, Boezen HM, Van der Graaf WT: The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer 2007, 43:1895-1904
40. Feng Y, Zhu Z, Xiao X, Choudhry V, Barrett JC, Dimitrov DS: Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mol Cancer Ther 2006, 5:114-120
41. Steller MA, Delgado CH, Bartels CJ, Woodworth CD, Zou Z: Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res 1996, 56:1761-1765